Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Expenditures (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Capital Expenditures readings, the most recent being $1.6 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 105.57% to $1.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.2 million, a 0.0% change, with the full-year FY2025 number at $2.2 million, changed 0.0% from a year prior.
  • Capital Expenditures hit $1.6 million in Q4 2025 for Neurocrine Biosciences, up from -$22.6 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $22.1 million in Q3 2023 to a low of -$28.7 million in Q4 2024.
  • Median Capital Expenditures over the past 5 years was $4.4 million (2021), compared with a mean of $1.3 million.
  • Biggest five-year swings in Capital Expenditures: crashed 4350.0% in 2021 and later surged 5700.0% in 2024.
  • Neurocrine Biosciences' Capital Expenditures stood at $1.6 million in 2021, then skyrocketed by 887.5% to $15.8 million in 2022, then tumbled by 229.11% to -$20.4 million in 2023, then crashed by 40.69% to -$28.7 million in 2024, then skyrocketed by 105.57% to $1.6 million in 2025.
  • The last three reported values for Capital Expenditures were $1.6 million (Q4 2025), -$22.6 million (Q3 2025), and $12.5 million (Q2 2025) per Business Quant data.